ReviewJournal of cardiovascular translational research2021
Adult Cardiomyocyte Proliferation: a New Insight for Myocardial Infarction Therapy.
Review in Journal of cardiovascular translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- METTL1/WDR4 Complex: A Novel Epitranscriptomic Target at the Crossroads of RNA Methylation and Drug Discovery.Journal of medicinal chemistry · 2026Review
- LncRNAiScience · 2026Article
- The Therapeutic Scope of Orofacial Mesenchymal Stem Cells.Bioengineering (Basel, Switzerland) · 2025Review
- Exercise Empowerment: A Multifaceted Anatomy in Managing Diabetic Myocardial Disorder.Journal of cardiovascular translational research · 2025Review
- PLAC8 as a potential therapeutic target for myocardial infarction: unraveling the molecular mechanisms.Journal of physiology and biochemistry · 2025Article
- PTMA controls cardiomyocyte proliferation and cardiac repair by enhancing STAT3 acetylation.Science advances · 2025Article
- Regenerative therapies for myocardial infarction: exploring the critical role of energy metabolism in achieving cardiac repair.Frontiers in cardiovascular medicine · 2025Review
- Two promising approaches in the treatment of myocardial infarction: stem cells and gene therapy.Frontiers in cardiovascular medicine · 2025Review
- Article
- Research progress on the natural products in the intervention of myocardial infarction.Frontiers in pharmacology · 2024Review
- Plasma leucine-rich α-2 glycoprotein 1 in ST-elevation myocardial infarction: vertical variation, correlation with T helper 17/regulatory T ratio, and predictive value on major adverse cardiovascular events.Frontiers in cardiovascular medicine · 2024Article
- Developmental Aspects of Cardiac Adaptation to Increased Workload.Journal of cardiovascular development and disease · 2023Review
- Systemic Hypoxemia Induces Cardiomyocyte Hypertrophy and Right Ventricular Specific Induction of Proliferation.Circulation research · 2023Article
- Berberine plays a cardioprotective role by inhibiting macrophage Wnt5a/β-catenin pathway in the myocardium of mice after myocardial infarction.Phytotherapy research : PTR · 2023Article
- Dynamic regulation of HIF-1 signaling in the rhesus monkey heart after ischemic injury.BMC cardiovascular disorders · 2022Article
- Review
- Induced Cardiomyocyte Proliferation: A Promising Approach to Cure Heart Failure.International journal of molecular sciences · 2021Review
- LncRNAs in Cardiomyocyte Maturation: New Window for Cardiac Regenerative Medicine.Non-coding RNA · 2021Review
- Hypoxia-induced amniotic fluid stem cell secretome augments cardiomyocyte proliferation and enhances cardioprotective effects under hypoxic-ischemic conditions.Scientific reports · 2021Article
- Exosomes released from mesenchymal stem cells overexpressing microRNA-30e ameliorate heart failure in rats with myocardial infarction.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction leads to cardiomyocyte loss, ensuing ventricular pathological remodeling, dramatic impairment of cardiac function, and ultimately heart failure. Unfortunately, the existing therapeutical treatments cannot directly replenish the lost myocytes in the injured myocardium and the long-term prognosis of heart failure after myocardial infarction remains poor. Growing investigations have demonstrated that the adult mammalian cardiomyocytes possess very limited proliferation capacity, and that was not enough to restore the injured heart. Recently, many studies were targeting to promote cardiomyocyte proliferation via inducing cardiomyocyte cell cycle re-entry for cardiac repair after myocardial infarction. Indeed, these results showed it is a feasible way to stimulate terminally differentiated cardiomyocyte proliferation. Here, we reviewed the major mechanisms and the potential targets for stimulating mammalian adult cardiomyocyte proliferation specifically. This will provide a new therapeutic strategy for the clinical treatment of myocardial infarction by activating the endogenous regeneration. Graphical abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.